Mineralys Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company dedicated to treating cardio-renal-metabolic conditions. The company's lead product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor. Lorundrostat is currently advancing through late-stage clinical trials for the treatment of uncontrolled and resistant hypertension, as well as chronic kidney disease. By focusing on the biological premise that excessive aldosterone production contributes significantly to high blood pressure and kidney dysfunction, Mineralys aims to provide a novel mechanism of action in the cardiovascular space. The company operates primarily in the United States and generates no commercial revenue, focusing entirely on research and development.
